Etemadifar M, Janghorbani M, Shaygannejad V
Dept. of Neurology and Epidemiology, Isfahan University of Medical Sciences and Health Services, Iran.
J Neurol. 2007 Dec;254(12):1723-8. doi: 10.1007/s00415-007-0637-1. Epub 2007 Dec 14.
We compared the relative efficacy of interferon beta (IFNbeta) products and azathioprine (AZA) in the treatment of relapsing- remitting multiple sclerosis (RRMS). Ninety-four previously untreated patients of short duration with RRMS were randomly allocated to the two treatment groups. The first group received IFNbeta products (Betaferon,Avonex or Rebif); the second group received AZA for 12 months. Response to treatment was assessed at 3, 6, and 12 months after starting therapy. The mean number of relapse during one year of the study was lower in the AZA group than in the IFNbeta products group (0.28 vs. 0.64, P < 0.05). After 12 months, 57.4% of patients receiving IFNbeta products remained relapse free compared with 76.6% of those given AZA. The Expanded Disability Status Scale (EDSS) decreased by 0.30 units in IFNbeta-treated patients (P < 0.05) and 0.46 in AZAtreated patients (P < 0.001). Treatment with IFNbeta products and AZA significantly reduces the relapse rate and EDSS score in patients with RRMS, while AZA is more effective than the IFNbeta formulations.
我们比较了β-干扰素（IFNβ）产品和硫唑嘌呤（AZA）在治疗复发缓解型多发性硬化症（RRMS）中的相对疗效。94例病程较短、未经治疗的RRMS患者被随机分配到两个治疗组。第一组接受IFNβ产品（β-干扰素、阿沃尼单抗或利比）治疗；第二组接受AZA治疗12个月。在开始治疗后的3个月、6个月和12个月评估治疗反应。在研究的一年中，AZA组的平均复发次数低于IFNβ产品组（0.28对0.64，P<0.05）。12个月后，接受IFNβ产品治疗的患者中有57.4%无复发，而接受AZA治疗的患者中这一比例为76.6%。在IFNβ治疗的患者中，扩展残疾状态量表（EDSS）下降了0.30个单位（P<0.05），在AZA治疗的患者中下降了0.46个单位（P<0.001）。IFNβ产品和AZA治疗可显著降低RRMS患者的复发率和EDSS评分，而AZA比IFNβ制剂更有效。
